Coronary Artery Calcium Scoring: The Single Best Test for Cardiovascular Risk Assessment
The coronary artery calcium (CAC) score measures the amount of calcified atherosclerotic plaque in the coronary arteries using a non-contrast CT scan — providing direct visualization of the atherosclerotic disease process rather than merely inferring it from risk factors. It is the single most powerful cardiovascular risk stratification tool available and is substantially underutilized in preventive medicine.
- The CAC score directly measures the extent of calcified atherosclerotic plaque in the coronary arteries — the actual disease rather than risk factors for disease. A CAC score of 0 in a person over 40 is one of the most reassuring findings available in preventive cardiology: it is associated with very low 10-year cardiovascular event rates even in people with multiple traditional risk factors.
- The MESA study (Multi-Ethnic Study of Atherosclerosis) established CAC as the most powerful predictor of cardiovascular events available, adding incremental prognostic value over traditional risk factors, the Framingham Risk Score, and even CRP. In MESA, a CAC above 300 was associated with a 7.7-fold increased risk of coronary heart disease events compared to CAC of 0.
- CAC scoring is particularly valuable in the 'intermediate risk' zone where traditional risk factor equations leave clinicians uncertain about statin therapy. A CAC of 0 typically down-classifies risk and can support deferral of statin therapy; a CAC above 100 typically up-classifies risk and supports more aggressive preventive treatment regardless of calculated risk score.
- The radiation dose from a CAC scan is low (approximately 1-2 mSv — comparable to a mammogram or 6 months of background radiation) and the scan takes less than 10 minutes with no contrast agent required. Cost: typically $75-150 at imaging centers, often self-pay as insurance coverage is inconsistent.
- CAC progression — the rate at which the calcium score increases over serial scans — is emerging as an important additional biomarker. Annual CAC progression above 15 Agatston units is associated with elevated cardiovascular event risk independent of baseline score. Some longevity physicians are using serial CAC scoring every 2-5 years to track atherosclerotic disease trajectory and assess treatment response.
Every cardiovascular risk calculator in clinical use — Framingham, PCE, SCORE2 — estimates risk based on risk factors: blood pressure, cholesterol, smoking, age, sex, diabetes status. These factors are causally linked to atherosclerosis, but they are proxies for the actual disease rather than measures of it. Coronary artery calcium scoring breaks this abstraction by directly measuring the calcified atherosclerotic plaque that has already accumulated in the coronary arteries — providing a window into the actual state of the cardiovascular system rather than an estimate based on inputs.1
What the CAC Score Measures
Coronary artery calcification occurs within established atherosclerotic plaques as a consequence of the inflammatory and degenerative processes that drive plaque formation. Calcium deposition is quantified using the Agatston method (which weights calcium density by area) to produce the CAC score. The score correlates with total plaque burden but specifically reflects the calcified component — which is generally more stable and less prone to rupture than soft, non-calcified plaque. A CAC score of 0 indicates no detectable calcified atherosclerotic plaque; scores above 400 indicate extensive calcification associated with substantially elevated event risk.2
The CAC scan is acquired as a non-contrast CT of the chest with cardiac gating to minimize motion artifact. The effective radiation dose is approximately 1 to 2 mSv — comparable to a mammogram or 6 months of natural background radiation. No intravenous contrast is required. The scan takes 10 to 15 minutes. Most imaging centers in the US offer CAC scoring for $75 to $150 as a self-pay service.
The MESA Data: Why CAC Is Unique
The Multi-Ethnic Study of Atherosclerosis (MESA) — a prospective cohort study of over 6,800 adults — established the prognostic power of CAC scoring with unusual rigor. The key findings: CAC added significant incremental prognostic value for cardiovascular events over and above the Framingham Risk Score, traditional risk factors, and CRP. Among people with intermediate calculated risk by Framingham score, CAC of 0 reclassified 53 percent to low risk; CAC above 300 reclassified to high risk. The hazard ratio for coronary heart disease events comparing CAC above 300 to CAC of 0 was 7.7 — one of the largest effect sizes in preventive cardiology.3
The CAC = 0 finding deserves specific emphasis. Across MESA and subsequent studies, a CAC score of 0 in adults over 40 is consistently associated with very low 10-year cardiovascular event rates — approximately 1 percent or less — even in people with multiple traditional risk factors including hypertension, hyperlipidemia, and diabetes. This is because CAC = 0 indicates that despite risk factor exposure, the coronary arteries have not yet developed detectable atherosclerotic disease. This finding can meaningfully reduce anxiety and allow consideration of statin therapy deferral in otherwise intermediate-risk individuals.
Who Should Get a CAC Score
The 2018 AHA/ACC cholesterol guidelines and the ACC/AHA ASCVD risk calculator specifically recommend CAC scoring for statin therapy decision-making in intermediate-risk adults (7.5 to 20 percent 10-year ASCVD risk) where the decision to start a statin is uncertain. The guidelines also suggest CAC can be considered in lower-risk adults where statin therapy is being considered and the benefit is uncertain. From a longevity medicine perspective, the indication is broader: any adult over 40 who wants to know their actual atherosclerotic disease burden — not just their calculated risk — is a reasonable candidate for a baseline CAC score.4
The most evidence-supported trigger for CAC ordering: family history of premature cardiovascular disease (first-degree relative with CVD before age 55 in men, 65 in women); LDL-C or ApoB persistently elevated despite lifestyle optimization (to determine statin necessity); intermediate calculated ASCVD risk where treatment decision is uncertain; and any person with calcium score concern who wants direct coronary artery assessment rather than risk factor proxies.
CAC Score Interpretation
| CAC Score | Interpretation | 10-Year Event Risk | Clinical Action |
|---|---|---|---|
| 0 | No detectable calcification | Very low (<1-2%) | Statin deferral reasonable; lifestyle focus; retest in 3-5 years if other risks |
| 1-99 | Mild calcification | Low to moderate | Intensify lifestyle; statin if risk factors present |
| 100-299 | Moderate calcification | Moderate to high | Statin therapy generally indicated; ApoB target below 70 mg/dL |
| 300-999 | Severe calcification | High | Aggressive ApoB lowering; consider PCSK9i; aspirin discussion |
| >1000 | Very severe | Very high | Cardiology referral; maximal medical therapy |
References
- 1Greenland P, et al. "ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring." JACC. 2007;49(3):378-402. [PubMed]
- 2Agatston AS, et al. "Quantification of coronary artery calcium using ultrafast computed tomography." JACC. 1990;15(4):827-832. [PubMed]
- 3Detrano R, et al. "Coronary calcium as a predictor of coronary events in four racial or ethnic groups." NEJM. 2008;358(13):1336-1345. [PubMed]
- 4Grundy SM, et al. "2018 AHA/ACC Guideline on the Management of Blood Cholesterol." JACC. 2019;73(24):e285-e350. [PubMed]
- 5Blaha MJ, et al. "Absence of coronary artery calcification and all-cause mortality." JACC: Cardiovascular Imaging. 2009;2(6):692-700. [PubMed]